EXACT SCIENCES Files 8-K on Operations & Officer Arrangements
Ticker: EXAS · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1124140
| Field | Detail |
|---|---|
| Company | Exact Sciences CORP (EXAS) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, financial-condition, officer-changes, disclosure
TL;DR
**EXACT SCIENCES filed a routine 8-K, no major news on financials or execs disclosed.**
AI Summary
EXACT SCIENCES CORP filed an 8-K on January 7, 2024, to report on its financial condition and operations, specifically regarding the departure or appointment of officers and their compensatory arrangements. This filing is a standard disclosure and does not contain specific dollar amounts or names of individuals, indicating no immediate major changes in leadership or financial results were announced. For investors, this means there's no new material information about the company's performance or executive team that would drastically alter their investment thesis based solely on this filing.
Why It Matters
This filing signals routine corporate governance and financial disclosure, but without specific details, it doesn't provide new actionable insights for investors regarding the company's immediate performance or strategic direction.
Risk Assessment
Risk Level: low — The filing is a standard disclosure without any specific negative or positive financial or operational news, indicating low immediate risk.
Analyst Insight
Investors should note this is a routine disclosure without specific new financial or executive details. Further investigation into the full filing or subsequent announcements would be needed for actionable insights.
Key Players & Entities
- EXACT SCIENCES CORP (company) — the registrant filing the 8-K
- January 7, 2024 (date) — date of earliest event reported
FAQ
What is the purpose of this 8-K filing by EXACT SCIENCES CORP?
This 8-K filing by EXACT SCIENCES CORP is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as of January 7, 2024.
What specific financial information is disclosed in this 8-K?
The filing indicates 'Results of Operations and Financial Condition' as an item, but the provided text does not contain specific dollar amounts, revenue figures, or detailed financial results. It merely states the category of information being reported.
Does this 8-K name any specific officers departing or being appointed?
No, the provided text of the 8-K filing does not name any specific individuals departing or being appointed, nor does it detail any compensatory arrangements for officers. It only lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as an item of information.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported in this 8-K is January 7, 2024.
What is the business address and phone number of EXACT SCIENCES CORPORATION as listed in the filing?
The business address of EXACT SCIENCES CORPORATION is 5505 Endeavor Lane, Madison, WI 53719, and its telephone number is (608) 284-5700.
Filing Stats: 705 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-08 07:03:45
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share EXAS The Nasdaq Sto
Filing Documents
- exas-20240107.htm (8-K) — 35KB
- exas-20240108xex991.htm (EX-99.1) — 29KB
- 0001124140-24-000003.txt ( ) — 226KB
- exas-20240107.xsd (EX-101.SCH) — 2KB
- exas-20240107_def.xml (EX-101.DEF) — 15KB
- exas-20240107_lab.xml (EX-101.LAB) — 28KB
- exas-20240107_pre.xml (EX-101.PRE) — 15KB
- exas-20240107_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXACT SCIENCES CORPORATION Date: January 8, 2024 By: /s/ Jeffrey T. Elliott Jeffrey T. Elliott Executive Vice President and Chief Financial Officer 3